Contact
searchSearch
HMP Global
ISET 2026

Retrievable Scaffold Therapy: Results From Trials

S. Jay Mathews, MD, MS, FACC, FSCAI
04/07/2026

In this video, interventional cardiologist S. Jay Mathews, MD, MS, FACC, FSCAI, from Bradenton Cardiology Center in Florida, shares key insights from his ISET 2026 presentation, “Retrievable Scaffold Therapy: Update From Trials”. Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.

Related Content

Bioresorbable Scaffolds
REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Critical Limb-Threatening Ischemia Patients
04/23/2026
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its...
04/23/2026
Cath Lab Digest
Interview
Tackling the Calcium Challenge: Managing Recoil, Rupture, and Occlusion
04/22/2026
Kumar Madassery, MD
Dr Madassery explores why calcified lesions continue to complicate treatment.
Dr Madassery explores why calcified lesions continue to complicate treatment.
Dr Madassery explores why...
04/22/2026
Vascular Disease Management
BTK Intervention
Abbott Unveils Post-Approval Study Data Demonstrating Potential of Esprit BTK to Treat Significantly Sicker Patients with CLTI and Complex Lesions
04/21/2026
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the...
04/21/2026
Cath Lab Digest
Femoropopliteal Disease
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
04/21/2026
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif....
04/21/2026
Cath Lab Digest

Stay in the Know

Vascular Disease Management Newsletter

News

Bioresorbable Scaffolds
REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Critical Limb-Threatening Ischemia Patients
04/23/2026
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its...
04/23/2026
Cath Lab Digest
BTK Intervention
Abbott Unveils Post-Approval Study Data Demonstrating Potential of Esprit BTK to Treat Significantly Sicker Patients with CLTI and Complex Lesions
04/21/2026
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the...
04/21/2026
Cath Lab Digest
Chronic Venous Disease
InVera Medical Reports 12-Month Results From Pilot Trial of InVera Infusion Device Showing Vein Closure in 90% of Patients, Statistically Significant Quality of Life Improvements, and Excellent Safety
04/21/2026
Novel Non-Thermal Procedure for Chronic Venous Disease Designed to Effectively Eliminate Need for Painful Injections Required for Thermal Ablation
Novel Non-Thermal Procedure for Chronic Venous Disease Designed to Effectively Eliminate Need for Painful Injections Required for Thermal Ablation
Novel Non-Thermal Procedure for...
04/21/2026
Vascular Disease Management
Femoropopliteal Disease
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
04/21/2026
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif....
04/21/2026
Cath Lab Digest
Arteriovenous Fistula
Medtronic Reports Strong 12-Month Real-World Outcomes for IN.PACT™ AV Drug-Coated Balloon†
04/16/2026
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1 Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1 Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary...
04/16/2026
Vascular Disease Management
AMP 2026
AMP Ahead: HMP Global’s AMP 2026 Advances the Future of CLTI Innovation and Education
04/16/2026
August 5-8 event at new location in Boston highlights DVA, drug-eluting tech, eight first-to-podium research presentations, and featuring a cadaver lab.
August 5-8 event at new location in Boston highlights DVA, drug-eluting tech, eight first-to-podium research presentations, and featuring a cadaver lab.
August 5-8 event at new location...
04/16/2026
Vascular Disease Management
Reflow Medical Spur System
Peripheral Intervention
Reflow Medical Announces 12-Month Results from DEEPER REVEAL Trial: Sustained Outcomes with the Spur® Stent System in CLTI
04/15/2026
DEEPER REVEAL is a prospective, non-randomized, multicenter study evaluating use of the Spur Peripheral Retrievable Stent System following predilatation in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee (BTK)...
DEEPER REVEAL is a prospective, non-randomized, multicenter study evaluating use of the Spur Peripheral Retrievable Stent System following predilatation in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee (BTK)...
DEEPER REVEAL is a prospective,...
04/15/2026
Cath Lab Digest
Novel Local Therapies
Pulsed Electric Field Ablation Plus SBRT Preserves Quality of Life in Lung Tumors
04/13/2026
Laura Simson, MA
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study...
04/13/2026
Vascular Disease Management
Pulmonary Embolism
New STORM-PE Data Show Computer-Assisted Vacuum Thrombectomy With Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients 
04/13/2026
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
“Together with the initial STORM...
04/13/2026
Cath Lab Digest
Cook Medical’s Interventional iMRI Suite
MRI
Cook Medical and Siemens Healthineers Debut Integrated Interventional MRI Suite at SIR 2026
04/13/2026
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care. 
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care. 
iMRI enables a minimally...
04/13/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use